Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2018 Sep;15(9):541-563. doi: 10.1038/s41571-018-0035-x.

Clinical utility of circulating non-coding RNAs - an update.

Author information

1
Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
2
Department of Tumour Biology, Centre for Experimental Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
3
Department of Tumour Biology, Centre for Experimental Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.de.
4
Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. gcalin@mdanderson.org.
5
The Center for RNA Interference and Non-Coding RNAs, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. gcalin@mdanderson.org.

Abstract

Over the past decade, the amount of research and the number of publications on associations between circulating small and long non-coding RNAs (ncRNAs) and cancer have grown exponentially. Particular focus has been placed on the development of diagnostic and prognostic biomarkers to enable efficient patient management - from early detection of cancer to monitoring for disease recurrence or progression after treatment. Owing to their high abundance and stability, circulating ncRNAs have potential utility as non-invasive, blood-based biomarkers that can provide information on tumour biology and the effects of treatments, such as targeted therapies and immunotherapies. Increasing evidence highlights the roles of ncRNAs in cell-to-cell communication, with a number of ncRNAs having the capacity to regulate gene expression outside of the cell of origin through extracellular vesicle-mediated transfer to recipient cells, with implications for cancer progression and therapy resistance. Moreover, 'foreign' microRNAs (miRNAs) encoded by non-human genomes (so-called xeno-miRNAs), such as viral miRNAs, have been shown to be present in human body fluids and can be used as biomarkers. Herein, we review the latest developments in the use of circulating ncRNAs as diagnostic and prognostic biomarkers and discuss their roles in cell-to-cell communication in the context of cancer. We provide a compendium of miRNAs and long ncRNAs that have been reported in the literature to be present in human body fluids and that have the potential to be used as diagnostic and prognostic cancer biomarkers.

PMID:
29784926
DOI:
10.1038/s41571-018-0035-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center